Mylab Discovery Solutions, India’s leading biotechnology company has joined forces with the US-based Hemex Health, a medical diagnostic device company focused on creating life-changing global health products, to develop next-generation diagnostic solutions for the Point-of-Care (POC) testing of coronavirus and other diseases. Under the technology partnership, Mylab will develop test assays and Hemex will provide its Gazelle POC testing platform and expertise. After the second wave, the importance of decentralized testing has become evident due to limited capacity of traditional laboratories. The portable diagnostic device and tests assays will help in testing at any location, in a wide range of environmental conditions, and without the need to transport the sample, enabling quick result for the patients.

Together, the companies will Fluorescence Immunoassay (FIA) and Electrophoresis-based diagnostic solutions. These tests are more sensitive than the normal rapid antigen tests and have fewer false negatives. The diagnostic solution will be jointly introduced in the international markets including the United States, Europe and Asia. This collaboration will bring together deep knowledge in molecular diagnostic technology, product ideation, and new technology development and deployment to augment testing capabilities for Covid-19 around the world.

Commenting on the partnership, Hasmukh Rawal, MD, Mylab Discovery Solutions, said, “We are thrilled to partner with Hemex, which has deep expertise in developing portable Point of Care diagnostics machines. Together with Mylab’s accurate FIA test kits, we can make testing available anywhere – from a small village without electricity to an international airport. We believe this partnership will help India and the world prevent subsequent waves of Coronavirus”.

Patti White, CEO & Co-founder, Hemex Health, said, “We are excited to announce the partnership with Mylab to provide new breakthrough testing for Covid-19 and other diseases in the future. This past year, Mylab has demonstrated outstanding ability to move quickly to solve big challenges posed by Covid-19. We share the same drive to make a difference for the people.”

The Companies expect the first product from this technology partnership to be launched by November 2021. Hemex Health, backed by TiE Global Angels and Cleveland Clinic among other investors, has broad experience in the U.S. market and distributes a point-of-care sickle cell test on their Gazelle™ Diagnostic Device into nine countries. Mylab, backed by Adar Poonawalla of Serum Institute of India, has been leading the development of diagnostics solutions in India including the latest self-test kit – CoviSelf for Covid-19.